It refers to a method including effective treatment of 1 - ((3S, 4R) - 4 - (2, 6-difluoro-4-methoxyphenyl) - 2-oxoprolidin-3-il) - 3-phenyl (compound 1),It is administered orally for at least one, two or six weeks a day, in addition to a second agent selected from day care centres, central support group inhibitors, etc. This compound is an enhancer of type 2 goiter / lipoxina A4 (fpr2 / alx) receptor and can be used to treat and / or prevent heart failure.
展开▼
